Study type: In vivo/preclinical · Verification: Citation verified
Alzheimer's disease neuropathology is exacerbated following traumatic brain injury. Neuroprotection by co-administration of nanowired mesenchymal stem cells and cerebrolysin with monoclonal antibodies to amyloid beta peptide.
Progress in brain research · 2021
Study scale: Not reported in the declared source.
Bibliographic details only: Open source record
Product or molecular entity relationships
- Cerebrolysin: Catalog source association. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.
No public summary
No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.
Limitations and uncertainty
Not reported in the declared source.
Citation verified. The PMID shown was confirmed at PubMed on 2026-08-16, and its study type matched the catalog’s source record. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.